Dabrafenib plus trametinib dalam BRAFV600E -kanser jarang bermutasi: percubaan ROAR fasa 2 – Alam Semulajadi
Dabrafenib plus trametinib in BRAFV600E -mutated rare cancers: the phase 2 ROAR trial Nature
KESHAV
Maklumat ubat, indikasi, dos, dan keselamatan yang berkaitan dengan produk yang tersedia.
Dabrafenib plus trametinib in BRAFV600E -mutated rare cancers: the phase 2 ROAR trial Nature
KRYSTAL-10 at ESMO GI 2026: Adagrasib Plus Cetuximab vs Chemotherapy in KRAS G12C-Mutated mCRC Oncodaily
The European Commission (EC) has granted marketing authorisation for AbbVie’s Tepkinly (epcoritamab) in combination with lenalidomide and rituximab (Tepkinly + R²) for adult patien…
World J Urol:一项为期36个月的前瞻性研究揭示Benign prostatic hyperplasia水蒸气热疗缓解症状的预测因素-MedSci.cn 梅斯医学 MedSci